ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Above 50 Day Moving Average – Should You Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s stock price crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $113.84 and traded as high as $116.43. ProShares Ultra Nasdaq Biotechnology shares last traded at $112.85, with a volume of 8,019 shares.

ProShares Ultra Nasdaq Biotechnology Trading Down 2.3%

The business has a 50 day moving average of $113.91 and a two-hundred day moving average of $98.86. The firm has a market cap of $92.64 million, a P/E ratio of 20.68 and a beta of 1.20.

Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology

A number of hedge funds have recently bought and sold shares of the business. Capital Investment Advisors LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the third quarter worth approximately $658,000. Toth Financial Advisory Corp acquired a new position in ProShares Ultra Nasdaq Biotechnology during the 3rd quarter worth about $118,000. Finally, Kaizen Financial Strategies raised its holdings in ProShares Ultra Nasdaq Biotechnology by 4.7% during the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock worth $483,000 after purchasing an additional 250 shares during the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.